Nov 10, 2022 · A Phase III Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stage II/III Non-Small Cell Lung Cancer (AEGEAN)

We report key surgical outcomes from AEGEAN.

The Agean Range has been manufactured to fuse style and performance using high quality, stain resistant, solution dyed nylon yarn. With its’ low profile, dense construction delivering superior …

FDA agrees that this addendum provides updated efficacy and safety results from the third pre-planned analysis of AEGEAN.

The Committee will discuss supplemental biologics license application (sBLA) 761069/S-043, for IMFINZI (durvalumab) injection, submitted by AstraZeneca UK Limited.

Aug 14, 2023 · AEGEAN is an ongoing, Phase III, double-blind, placebo-controlled, randomized, multicenter, international study assessing the efficacy and safety of durvalumab in combination …

Notes: (1) EBITDAR is a term commonly used in the airline industry and generally refers to earnings before net interest expense, income taxes, depreciation and amortization and rental …